reports
EQS-News: Mainz Biomed präsentierte branchenführende Ergebnisse seiner...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort(e): Studienergebnisse/Konferenz Mainz Biomed präsentierte branchenführende Ergebnisse seiner gepoolten Studie auf dem ASCO 2024 03.06.2024 / 14:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Mainz Biomed präsentierte branchenführende Ergebnisse seiner gepoolten Studie auf dem ASCO 2024 Die neuen Daten bestätigen die Ergebnisse der ColoFuture- und eAArly-DETECT-Studien mit einer Sensitivität von 92% für Darmkrebs und 82% für fortgeschrittene Adenome, sowie 95,8% für die Erkenn...
EQS-News: Mainz Biomed Presented Industry Leading Results of its Poole...
Issuer: Mainz BioMed N.V. / Key word(s): Study results/Conference Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 03.06.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecu...
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK C...
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic...
InnovAge PACE Recertified as a Great Place to Work
InnovAge PACE Recertified as a Great Place to Work PACE Program Provides Highly Coordinated, Personalized Senior Care DENVER, June 03, 2024 (GLOBE NEWSWIRE) -- (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE) has been recertified as a Great Place to Work. “Earning this badge of honor is a reflection of the strength, credibility, and camaraderie of the InnovAge team,” says InnovAge President and CEO Patrick Blair. “All of us are driven ...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Co...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and available under “...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed’s mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagno...
Medicenna Reports Significant Survival Benefit in Patients with Recurr...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL-4 receptor (IL-4R) expression in unresectable recurrent glioblastoma (rGBM) patients in the Phase 2b Study Biz...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for M...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development tow...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Presents Clinical Efficacy Data at ASCO 2024 Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patientsTherapy well-tolerated with no Bria-IMT™ related discontinuationsClinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancerSuperiority of selected Phase 3 regimen and formulation confirmedOral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD, on Monday June 3; 11:30 AM-1:00 PM CDT PHILADELPHIA and VANCOUVER, British Columbia, June 03, 2024 (...
Charles River Laboratories to Present at William Blair and Jefferies C...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:00 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River we...
Westwood Announces Monthly Income Distributions for Westwood Salient E...
Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST) and Westwood Salient Enhanced Energy Income ETF (WEEI) DALLAS, June 03, 2024 (GLOBE NEWSWIRE) -- (WHG), a publicly-traded investment management boutique and wealth management firm, today announced monthly income distributions for and as shown in the table below. This pair of deliver income from both dividends and options premiums to help provide monthly income distributions for investors. Most recently, both strategies are providing double-digit income to investors. ETF Ticker...
Enlivex Receives Regulatory Authorization for the Initiation of a Plac...
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis ● First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy ●Third study of AllocetraTM in osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage knee osteoarthritis, and the on-going randomized, placebo-controlled Phase I/II trial in up to 160 moderately to severely symptomatic knee osteoarthritis...
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Heal...
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation...
PetMed Express, Inc. Announces Strategic Updates to Executive Leadersh...
PetMed Express, Inc. Announces Strategic Updates to Executive Leadership Team Caroline Conegliano appointed Chief Operating Officer Umesh Sripad appointed Chief Digital and Technology Officer Company Announces CFO transition DELRAY BEACH, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- , dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company") today announced several changes to its executive leadership team to further advance key initiatives to improve the customer experience, and to accelerate growth and profitability. Chief Operating Officer Caroline Conegliano joins Pe...
Aquestive Therapeutics Announces Executive Appointments and Builds Com...
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities Sherry Korczynski joins the leadership team as Senior Vice President, Sales and MarketingDr. Stephen Wargacki promoted to Chief Science OfficerCassie Jung named Chief Operating Officer WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it has strengthened its lead...
CSW Industrials Names Darron Ash to Board of Directors, Supporting Com...
CSW Industrials Names Darron Ash to Board of Directors, Supporting Commitment to Disciplined Capital Allocation, Corporate Responsibility and Board Succession Planning DALLAS, June 03, 2024 (GLOBE NEWSWIRE) -- CSW Industrials, Inc. (the “Company") (NASDAQ: CSWI) today announced that its Board of Directors has elected Darron Ash as an independent director. Mr. Ash’s addition as a director is part of the Board’s succession planning process and comes in anticipation of upcoming age-based director retirements pursuant to the Company’s Corporate Governance Guidelines. Mr. Ash brings deep ex...
KULR Announces Expiration of SEPA Facility and Compliance with NYSE Gu...
KULR Announces Expiration of SEPA Facility and Compliance with NYSE Guidelines on Audit Opinion Disclosure SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today announced that it will not be extending its Standby Equity Purchase Agreement (“SEPA”), with YA II PN, LTD. ("Yorkville"), which terminated on June 1, 2024. Furthermore, the Company confirms that it has retired all outstanding debt owed to Yorkville. This marks a significant milestone for KULR as it executes its strategic initiatives,...
VCI Global Gives Full Year Guidance After Seeing Revenues Increase Ove...
VCI Global Gives Full Year Guidance After Seeing Revenues Increase Over 145% in 2023 KUALA LUMPUR, Malaysia, June 03, 2024 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, “VCIG”, or the “Company”), a diversified holding company focusing on consulting and technology, announces revenue guidance for the fiscal year of 2024. "VCI Global delivered a strong financial year that exceeded expectations across key metrics. We gained market share with positive comparable sales demonstrating improved relevance with our business model. The milestone that we have executed so far ...
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1...
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting. Entera’s EB612 program aims to provide the first oral PTH daily tabl...
LiveOne to Host Special Investor Webcast to Provide Update on Strategi...
LiveOne to Host Special Investor Webcast to Provide Update on Strategic Partnerships, B2B Pipeline and Addressable Market for all Subsidiaries - Date: Wednesday, June 5, 2024-Time: 10:00 a.m. ET / 7:00 a.m. PT LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- LiveOne (Nasdaq: ), an award-winning, creator-first, music, entertainment and technology platform, plans to host a webcast to announce an update on its current major partnerships, pipeline B2B partnerships, and the overall size of the market for each subsidiary, showcasing its progress and growth initiatives. LiveOne's senior manageme...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.